Experience of X-linked hypophosphatemic rickets in the Gulf Cooperation Council countries: case series.
Fahad Al-JuraibahAdnan Al ShaikhAfaf Al-SagheirAmir BabikerAsma Al NuaimiAyed Al EneziGeorge S MikhailHassan A MundiHubert K PenninckxHuda MustafaMajid Al AmeriMohamed Al-DubayeeNadia S AliNagla FawzySameer Al ShammariTarek FiadPublished in: Endocrinology, diabetes & metabolism case reports (2024)
Conventional therapy resulted in a suboptimal response, with a lack of improvement of clinical signs and symptoms. Side effects of conventional therapy included nausea, diarrhea, abdominal pain, nephrocalcinosis, and hyperparathyroidism, which affected the patients' quality of life and adherence to treatment. Burosumab demonstrated marked improvements in the biochemical markers of rickets, in addition to reducing pain, muscle weakness, and fatigue. There were no significant side effects associated with burosumab therapy.
Keyphrases
- end stage renal disease
- abdominal pain
- chronic kidney disease
- chronic pain
- ejection fraction
- skeletal muscle
- sleep quality
- type diabetes
- prognostic factors
- stem cells
- peritoneal dialysis
- metabolic syndrome
- neuropathic pain
- bone marrow
- mesenchymal stem cells
- physical activity
- adipose tissue
- patient reported outcomes
- irritable bowel syndrome